Liquid biopsy, encompassing circulating tumor (ctDNA) and circulating tumor cells, is under investigation to overcome spatial and temporal heterogeneity of metastatic colorectal cancer. Limited comparative data are available. In a cohort of 20 patients, we show that ctDNA was detectable in all cases, whereas circulating tumor cells were detectable in one-third of cases. ctDNA analysis appears readily available to be a candidate for clinical application in metastatic colorectal cancer. Background: Tissue biopsy is the gold standard for tumor genotyping, but it is an invasive procedure providing a single snapshot into tumor heterogeneity. Liquid biopsy approaches, encompassing the analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), have been proposed as an alternative, with the potential of providing a comprehensive portrait of the tumor molecular landscape. In metastatic colorectal cancer (mCRC), both CTCs and ctDNA analysis have been investigated, but comparative analyses are limited. Methods: We collected blood samples from 20 consecutive patients with mCRC with at least 1 of the following inclusion criteria: high tumor burden (> 1 metastasis), intact colonic primary tumor, disease progression at the time of sampling, 2 cycles of cytotoxic chemotherapy of current treatment course, and time between last chemotherapy cycle ! 4 weeks. Results: Nineteen of 20 samples displayed the appropriate quality for CTC analysis. CTCs could be isolated in 7 (36.8%) of 19 evaluable patients. The median number of CTCs was 0 (range, 0-73). In 2 patients, we isolated > 1 CTC, and in five, we found 1 CTC. We retrieved ctDNA in all samples, with a median amount of 732,573 GE/mL (range, 174,078,615 GE/ mL). Concordance between ctDNA and tissue for RAS, BRAF, and ERBB2 alterations was found in 11 (84.6%) of 13 cases. Conclusions: In this cohort, we show that ctDNA was detectable in all cases, whereas CTCs were detectable in one-third of the cases. ctDNA analysis was achieved with a smaller amount of blood sampling and allowed molecular characterization. Our data indicate that ctDNA is a readily available candidate for clinical application in mCRC.
Introduction
Recent technical advances for molecular diagnosis have made it possible to obtain molecular information on tumors from peripheral blood through "liquid biopsy." This approach relies mainly on 2 different sources of circulating genetic information, circulating tumor cells (CTCs) and cell-free tumor DNA (ctDNA).
It has been already established that, in metastatic colorectal cancer (mCRC), the number of CTCs before and during treatment is a strong predictor of survival, 1 and enumeration of CTCs using the CellSearch system (Janssen Diagnostics, LLC, Raritan, NJ) is United States Food and Drug Administration-approved for monitoring of patients. Advantages of isolation and functional characterization of CTCs include the potential for comprehensive analysis (ie, protein expression, activation of signaling pathways, quantitative RNA analysis, and cytogenetic characterization) virtually achievable also at the single-cell level 2 and establishment of CTC-derived explants, 3 whereas the major drawback of this method is that CTCs are rare, with an estimate of 1 CTC per 106 to 108 normal blood cells. 4 CTC enrichment methods include an epithelial cell adhesion molecule (EpCAM)-based selection system, which may fail to detect cells that undergo mesenchymal transition, 4 and EpCAMindependent isolation systems that are limited by high cell-to-cell variability, necessitating isolation of a large number of CTCs to obtain a representative profile of the individual cancer genome. 5 The other side of the coin is represented by ctDNA, which is an EpCAM-independent, noninvasive biomarker, that can also be isolated from plasma or serum and other body fluids. Its association with prognosis in patients with mCRC has been clearly demonstrated, 6 and it also has the potential for monitoring minimal residual disease in earlier stages. 7 Additionally, several studies from our group and others have already demonstrated concordance of liquid biopsies and tumor-tissue biopsies for molecular characterization of clinically validated biomarkers such as RAS mutations, 8, 9 and that longitudinal analysis of ctDNA can be used to explore dynamic tumor evolution during targeted treatment in patients with mCRC. 8, [10] [11] [12] However, translation of this knowledge into better patient selection for treatment with molecularly targeted agents has yet to be demonstrated. Although both liquid biopsy methods are being increasingly proposed in various tumors including CRC, very limited comparative data are available between analysis of ctDNA and CTCs. 6 With this study, we aimed to test their performance in terms of successful detection as biomarkers in patients with mCRC.
Materials and Methods

Patients
We collected blood samples from 20 consecutive patients with mCRC treated at Niguarda Cancer Center, Milano, Italy, with at least 1 of the following inclusion criteria: high tumor burden (> 1 metastasis), intact colonic primary tumor, disease progression at the time of sampling, 2 cycles of cytotoxic chemotherapy of current treatment course, and time between last chemotherapy cycle ! 4 weeks. Samples were obtained through protocols approved by the local Ethical Committee at Ospedale Niguarda, Milano, Italy. All patients signed and provided their informed consent before sample collection.
Circulating Tumor DNA Analysis
At least 6 mL of whole blood was collected by blood draw using EDTA as an anticoagulant. Plasma was separated within 5 hours through 2 different centrifugation steps (the first at room temperature for 10 minutes at 1600 g and the second at 3000 g for the same time and temperature), obtaining up to 3 mL of plasma. Only 1 mL of plasma was used for subsequent mutational analysis. ctDNA was isolated from plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's instructions. Mutational analysis was carried out by droplet digital PCR (ddPCR) as follows: isolated ctDNA was amplified using ddPCR Supermix for Probes (Bio-Rad) using KRAS, NRAS, EGFR (custom-designed), and ERBB2 CNV. ddPCR was then performed according to manufacturer's protocol, and the results were reported as the percentage or fractional abundance (FA) of mutant DNA alleles to total (mutant plus wild-type) DNA alleles or copy number variations. In details, 8 to 10 mL of DNA template was added to 10 mL of ddPCR Supermix for Probes (Bio-Rad) and 2 mL of the primer and probe mixture. This reaction mix was added to a DG8 cartridge together with 60 mL of Droplet Generation Oil for Probes (Bio-Rad) and used for droplet generation. Droplets were then transferred to a 96-well plate (Eppendorf) and then thermal cycled with the following conditions: 5 minutes at 95 C, 40 cycles of 94 C for 30 seconds, 55 C for 1 minute, followed by 98 C for 10 minutes (Ramp Rate 2 C/s). Droplets were analyzed with the QX200 Droplet Reader (Bio-Rad) for fluorescent measurement of FAM and HEX probes. Gating was performed based on positive and negative controls, and mutant populations were identified. The ddPCR data were analyzed with QuantaSoft analysis software (Bio-Rad) to obtain FA and copy number variations of the mutated or amplified DNA alleles in the wild-type or normal background. The quantification of the target molecule was presented as number of total copies (mutant plus WT) per sample in each reaction. FA is calculated as follows: 
Genome Equivalent Quantification
ctDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's instructions. We used 6 mL of ctDNA as template for each reaction.
All samples were analyzed in triplicate. PCR reactions were performed using a 10-mL final volume containing 5 mL of GoTaq qPCR Master Mix, 2Â with CXR reference dye (Promega) and LINE-1 (12.5 mmol) forward and reverse primers. DNA at known concentrations was also used to build the standard curve.
CTC Enumeration
Blood (10 mL) was drawn into CellSave tubes (Janssen Diagnostics) for CTC enumeration using the CellSearch platform as previously described. 3 In brief, CTCs were identified as cells coexpressing EpCAM and cytokeratins (8, 18 , and 19) without expression of the white blood cell surface marker, CD45. The CellSearch Epithelial Cell Kit (Veridex) contains ferrofluid particles coated with anti EpCAM antibodies, 2 phycoerythrin-conjugated and allophycocyanin-conjugated antibodies specifically directed against cytokeratins and CD45 respectively. 4 0 ,6-diamidino-2-phenylindole (DAPI) staining was performed to identify fragmented and condensed nuclei representative of apoptotic cells. The
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Results
A total of 19 of 20 samples displayed the appropriate quality for CTC analysis. CTCs could be isolated in 7 (36.8%) of 19 evaluable patients, whereas ctDNA was retrieved in 20 (100.0%) of 20 (2-tailed P < .0001 by the Fisher exact test) ( Table 1 ). The median number of CTCs was 0 (range, 0-73). In 2 patients, we isolated > 1 CTC, and in 5 cases, we found 1 CTC. The median amount of ctDNA was 732,573 GE/mL (range, 174,774-174,078,615 GE/ mL). The 2 patients having > 1 CTC had a significantly higher average amount of ctDNA (GE/mL) than those without CTCs in their blood draws (P < .005). In contrast, no statistically significant difference in ctDNA amount was found among patients with 1 CTC. Candidate mutation analysis in ctDNA for RAS, BRAF, and ERBB2 alterations, performed only in those samples in which the respective alteration was known from tissue analysis, revealed a concordance in 11 (84.6%) of 13 cases as compared with tissue analysis. Tissue genotyping was performed on archival specimens obtained from primary tumor in 15 (75.0%) of 20 and metastatic sites in 5 (25%) of 20. Genotyping on CTCs was not carried out because they were detected only in 7 (35%) of 20 cases and because of the paucity of CTCs isolated using the CellSearch platform (median number, 0) overall, making the comparison poorly informative and technically challenging without undertaking a single-cell analysis.
Discussion
In this comparative cohort of paired liquid biopsies taken from patients with mCRC, we show that ctDNA was detectable in all cases, whereas CTCs retrieved by the CellSearch method were detectable in about one-third of cases. ctDNA analysis was achieved with a smaller amount of whole blood sampling (6 vs. 10 mL for ctDNA and CTCs, respectively) and allowed molecular characterization.
Limitations of our study include the lack of comparative molecular characterization with both methods. In our cohort, we performed candidate mutation analysis of selected relevant/drugable CRC oncogenes on ctDNA only, confirming that this is a reliable source for genotyping. 8 A recent report has shown that, in 15 patients with mCRC, using the label-free microfluidic platform Vortex Chip, an enumeration of 0.1 to 29 putative CTCs/mL (mean, 3.4/mL) has been retrieved, with the cutoff for defining positivity set at 0.4 CTCs per mL of blood based on the background noise in healthy donors. 13 In 9 of these, a comparative analysis between ctDNA and tissue was performed, showing that, in some samples, CTCs revealed a mutation that was not detected in ctDNA and vice versa, supporting that both methods are needed to enable optimal surveillance of the course of disease and treatment selection. In contrast, Bettegowda et al, by extracting DNA and performing 
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whole-genome sequencing of tumor DNA from plasma as well as from the cellular compartment of blood obtained after centrifugation, did not identify, in a cohort of 16 patients including 9 with CRC, any cases in which CTCs were detected but in which ctDNA was absent; further, in many cases in which ctDNA was detected (13 of 16; 81%), no CTCs were found. 6 
Conclusion
In conclusion, our data expand on, in a larger comparative series of individual patients with CRC and strictly focused on the metastatic setting, previous observations 6 indicating that ctDNA analysis is a more readily available candidate than CTCs for clinical application in mCRC.
Clinical Practice Points
Tumor heterogeneity hampers clinical efficacy of targeted therapies in CRC, and tissue biopsy is the gold standard to obtain the tumor molecular make-up before initiating treatment. Liquid biopsy, encompassing the analysis of ctDNA or CTCs, has been suggested as an alternative with the potential of providing the comprehensive tumor molecular landscape. Both CTCs and ctDNA analysis are under investigation in CRC; however, available comparative data are limited. In a cohort of 20 patients with metastatic CRC, ctDNA was detected in all of them, enabling the retrieval of main genetic alterations with a high concordance if compared with tissue biopsy. By contrast, CTC analysis required a higher amount of blood and was successful in only one-third of patients. ctDNA analysis is more likely to be successfully performed than CTCs analysis in metastatic CRC, making it a readily available candidate for clinical application.
